{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:38:37Z","timestamp":1793129917797,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001455","name":"American Foundation for Suicide Prevention","doi-asserted-by":"publisher","award":["DIG-1-037-19"],"award-info":[{"award-number":["DIG-1-037-19"]}],"id":[{"id":"10.13039\/100001455","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2024-02228"],"award-info":[{"award-number":["2024-02228"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2024-02766"],"award-info":[{"award-number":["2024-02766"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2024-06592"],"award-info":[{"award-number":["2024-06592"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jaac.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T01:23:23Z","timestamp":1769131403000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Second-Generation Antipsychotics and Real-World Outcomes in Youth With On- and Off-Label Indications"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-5103","authenticated-orcid":false,"given":"Le","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6770-8762","authenticated-orcid":false,"given":"Patrick D.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-9990","authenticated-orcid":false,"given":"Johan","family":"Bjureberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8375-9447","authenticated-orcid":false,"given":"Clara","family":"Hellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8576-3565","authenticated-orcid":false,"given":"Linnea","family":"Sepe-Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3800-6665","authenticated-orcid":false,"given":"Isabell","family":"Brikell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-2067","authenticated-orcid":false,"given":"Ralf","family":"Kuja-Halkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4471-289X","authenticated-orcid":false,"given":"Tanya E.","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5248-7434","authenticated-orcid":false,"given":"Brian M.","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8087-1417","authenticated-orcid":false,"given":"Zheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jaac.2026.01.009_bib1","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: a study in 16 countries, 2005\u20132014","volume":"27","author":"H\u00e1lfd\u00e1narson","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.jaac.2026.01.009_bib2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.acap.2024.03.003","article-title":"On- and off-label atypical antipsychotic prescription trends across a nine-year period among adolescents pre- to post-COVID-19","volume":"24","author":"Costales","year":"2024","journal-title":"Acad Pediatr"},{"issue":"9","key":"10.1016\/j.jaac.2026.01.009_bib3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2026.01.009_bib4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/jamapsychiatry.2017.3493","article-title":"Pediatric use of antipsychotic medications before and after Medicaid peer review implementation","volume":"75","author":"Zito","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/j.jaac.2026.01.009_bib5","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/pds.5032","article-title":"Spillover effects of state Medicaid antipsychotic prior authorization policies in US commercially insured youth","volume":"29","author":"Spence","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.jaac.2026.01.009_bib6","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/1475-6773.13297","article-title":"Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children","volume":"55","author":"Akincigil","year":"2020","journal-title":"Health Serv Res"},{"issue":"7","key":"10.1016\/j.jaac.2026.01.009_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1377\/hlthaff.2022.01625","article-title":"Antipsychotic medication use in Medicaid-insured children decreased substantially between 2008 and 2016","volume":"42","author":"Bushnell","year":"2023","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"10.1016\/j.jaac.2026.01.009_bib8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s11414-024-09889-0","article-title":"Descriptive trends in Medicaid antipsychotic prescription claims and expenditures, 2016\u20132021","volume":"51","author":"Giron","year":"2024","journal-title":"J Behav Health Serv Res"},{"issue":"2","key":"10.1016\/j.jaac.2026.01.009_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2215-0366(22)00404-7","article-title":"Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000\u201319 primary care data","volume":"10","author":"Radoj\u010di\u0107","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"10.1016\/j.jaac.2026.01.009_bib10","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00213-021-05809-8","article-title":"Psychotropic use in children and adolescents in Scandinavia and Catalonia: a 10-year population-based study","volume":"238","author":"G\u00f3mez-Lumbreras","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jaac.2026.01.009_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003784","article-title":"National trends in off-label use of atypical antipsychotics in children and adolescents in the United States","volume":"95","author":"Sohn","year":"2016","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.jaac.2026.01.009_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/JCP.0000000000000559","article-title":"Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry","volume":"36","author":"Bra\u00fcner","year":"2016","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.jaac.2026.01.009_bib13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s12888-021-03533-3","article-title":"Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018","volume":"21","author":"Candon","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2026.01.009_bib14","first-page":"19","article-title":"Neuroleptika vid vissa psykiatriska tillst\u00e5nd hos barn och ungdomar - behandlingsrekommendation: information fr\u00e5n L\u00e4kemedelsverket","volume":"27","year":"2016","journal-title":"L\u00e4kemedelsverket"},{"issue":"9","key":"10.1016\/j.jaac.2026.01.009_bib15","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ps.201900465","article-title":"Psychotropic use among youths with intellectual and developmental disabilities","volume":"72","author":"McLaren","year":"2021","journal-title":"Psychiatr Serv"},{"issue":"7","key":"10.1016\/j.jaac.2026.01.009_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.7850","article-title":"Antipsychotic treatment among youths with attention-deficit\/hyperactivity disorder","volume":"2","author":"Sultan","year":"2019","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.jaac.2026.01.009_bib17","first-page":"292","article-title":"Psychiatric hospitalization among adolescents","volume":"45","author":"Lalayants","year":"2018","journal-title":"J Behav Health Serv Res"},{"issue":"1","key":"10.1016\/j.jaac.2026.01.009_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/13623613221091316","article-title":"Suicidal ideation and intentional self-inflicted injury in autism spectrum disorder and intellectual disability: an examination of trends in youth emergency department visits in the United States from 2006 to 2014","volume":"27","author":"Cervantes","year":"2022","journal-title":"Autism"},{"key":"10.1016\/j.jaac.2026.01.009_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jpsychires.2021.02.053","article-title":"Estimating the risk of suicide associated with mental disorders: a systematic review and meta-regression analysis","volume":"137","author":"Moitra","year":"2021","journal-title":"J Psychiatr Res"},{"issue":"11","key":"10.1016\/j.jaac.2026.01.009_bib20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamapsychiatry.2019.1944","article-title":"Association of psychiatric comorbidity with the risk of premature death among children and adults with attention-deficit\/hyperactivity disorder","volume":"76","author":"Sun","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2026.01.009_bib21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.acap.2014.03.012","article-title":"Injuries among children with autism spectrum disorder","volume":"14","author":"Jain","year":"2014","journal-title":"Acad Pediatr"},{"issue":"2","key":"10.1016\/j.jaac.2026.01.009_bib22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S2215-0366(20)30262-5","article-title":"Violence and mental disorders: a structured review of associations by individual diagnoses, risk factors, and risk assessment","volume":"8","author":"Whiting","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.jaac.2026.01.009_bib23","article-title":"Atypical antipsychotics for disruptive behaviour disorders in children and youths","volume":"2017","author":"Loy","year":"2017","journal-title":"Cochrane Datab Syst Rev"},{"issue":"3","key":"10.1016\/j.jaac.2026.01.009_bib24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaac.2016.12.013","article-title":"Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis","volume":"56","author":"Pagsberg","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"10.1016\/j.jaac.2026.01.009_bib25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14737175.2017.1371012","article-title":"Efficacy of antipsychotics for irritability and aggression in children: a meta-analysis","volume":"17","author":"van Schalkwyk","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.jaac.2026.01.009_bib26","series-title":"First- and second-generation antipsychotics in children and young adults: systematic review update (Comparative Effectiveness Reviews, No. 184.)","author":"Pillay","year":"2017"},{"key":"10.1016\/j.jaac.2026.01.009_bib27","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/j.euroneuro.2006.06.002","article-title":"Meeting everyday challenges: antipsychotic therapy in the real world","volume":"16","author":"Gorwood","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.jaac.2026.01.009_bib28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamapsychiatry.2021.3990","article-title":"Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials","volume":"79","author":"Taipale","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2026.01.009_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euroneuro.2022.07.003","article-title":"The future of antipsychotics studies: how innovative designs may benefit patients with psychotic disorders","volume":"62","author":"Luykx","year":"2022","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jaac.2026.01.009_bib30","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jpeds.2021.06.062","article-title":"Real-world evidence for assessing treatment effectiveness and safety in pediatric populations","volume":"238","author":"Horton","year":"2021","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jaac.2026.01.009_bib31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/jamapsychiatry.2023.4573","article-title":"Antipsychotic medications and mortality in children and young adults","volume":"81","author":"Ray","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.jaac.2026.01.009_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamapsychiatry.2018.3421","article-title":"Association of antipsychotic treatment with risk of unexpected death among children and youths","volume":"76","author":"Ray","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/j.jaac.2026.01.009_bib33","first-page":"676","article-title":"Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics vs non-antipsychotics","volume":"18","author":"Sikirica","year":"2012","journal-title":"J Manag Care Pharm"},{"issue":"2","key":"10.1016\/j.jaac.2026.01.009_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2215-0366(23)00366-8","article-title":"Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data","volume":"11","author":"Efthimiou","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"10.1016\/j.jaac.2026.01.009_bib36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jaac.2026.01.009_bib37","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ (Clinical Research Ed)"},{"issue":"6","key":"10.1016\/j.jaac.2026.01.009_bib38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pds.5227","article-title":"Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology","volume":"30","author":"Cadarette","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.jaac.2026.01.009_bib39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S2215-0366(24)00104-4","article-title":"Target trial emulation in psychiatry: a call for more rigorous observational analyses","volume":"11","author":"Szmulewicz","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2026.01.009_bib40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamapsychiatry.2017.4704","article-title":"Enthusiasm and skepticism about using national registers to analyze psychotropic drug outcomes","volume":"75","author":"Leucht","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.jaac.2026.01.009_bib41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/08039488.2020.1854853","article-title":"Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences","volume":"75","author":"Taipale","year":"2021","journal-title":"Nord J Psychiatry"},{"key":"10.1016\/j.jaac.2026.01.009_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejim.2018.11.011","article-title":"Antipsychotics and severe hyponatremia: a Swedish population-based case\u2013control study","volume":"60","author":"Falhammar","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaac.2026.01.009_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2020.03.024","article-title":"Associations between selective serotonin reuptake inhibitors and violent crime in adolescents, young, and older adults\u2014a Swedish register-based study","volume":"36","author":"Lagerberg","year":"2020","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9949","key":"10.1016\/j.jaac.2026.01.009_bib44","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(14)60379-2","article-title":"Antipsychotics, mood stabilisers, and risk of violent crime","volume":"384","author":"Fazel","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jaac.2026.01.009_bib45","series-title":"Modeling Discrete Time-to-Event Data","author":"Tutz","year":"2016"},{"issue":"1","key":"10.1016\/j.jaac.2026.01.009_bib46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev-statistics-030718-105108","article-title":"Self-controlled case series methodology","volume":"6","author":"Whitaker","year":"2019","journal-title":"Annu Rev Stat Appl"},{"issue":"4","key":"10.1016\/j.jaac.2026.01.009_bib47","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/pds.4959","article-title":"Impact of pre-exposure time bias in self-controlled case series when the event conditions the exposure: hip\/femur fracture and use of benzodiazepines as a case study","volume":"29","author":"Requena","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaac.2026.01.009_bib48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev-statistics-030718-105108","article-title":"Self-controlled case series methodology","volume":"6","author":"Whitaker","year":"2019","journal-title":"Annu Rev Stat Appl"},{"issue":"4","key":"10.1016\/j.jaac.2026.01.009_bib49","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1097\/j.pain.0000000000002790","article-title":"Association between prescribed opioid dose and risk of motor vehicle crashes","volume":"164","author":"Quinn","year":"2023","journal-title":"Pain"},{"issue":"9","key":"10.1016\/j.jaac.2026.01.009_bib50","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pds.5083","article-title":"Time-related biases in pharmacoepidemiology","volume":"29","author":"Suissa","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.jaac.2026.01.009_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/schbul\/sbaa111","article-title":"Comparative effectiveness of antipsychotics for risk of attempted or completed suicide among persons with schizophrenia","volume":"47","author":"Taipale","year":"2021","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2026.01.009_bib52","article-title":"Real-world effectiveness of mood stabilizers on self-harm and suicide attempts in patients with bipolar disorder: a 2-year mirror-image study","volume":"3","author":"Jefsen","year":"2021","journal-title":"J Aff Disord Rep"},{"issue":"8","key":"10.1016\/j.jaac.2026.01.009_bib53","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bdi.12018","article-title":"Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study","volume":"14","author":"Nielsen","year":"2012","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jaac.2026.01.009_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115236","article-title":"Association between the mood stabilizing treatment of bipolar disorder and risk of suicide attempts: a self-controlled case series study","volume":"325","author":"Ng","year":"2023","journal-title":"Psychiatry Res"},{"issue":"8","key":"10.1016\/j.jaac.2026.01.009_bib55","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1176\/appi.ajp.2017.16050542","article-title":"Suicidal behavior during lithium and valproate treatment: a within-individual 8-year prospective study of 50,000 patients with bipolar disorder","volume":"174","author":"Song","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"11","key":"10.1016\/j.jaac.2026.01.009_bib56","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1177\/02698811221131990","article-title":"Association between quetiapine use and self-harm outcomes among people with recorded personality disorder in UK primary care: a self-controlled case series analysis","volume":"36","author":"Hayes","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"e1","key":"10.1016\/j.jaac.2026.01.009_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/ebmental-2022-300493","article-title":"Associations between antipsychotics and risk of violent crimes and suicidal behaviour in personality disorder","volume":"25","author":"Herttua","year":"2022","journal-title":"Evid Based Ment Health"},{"issue":"12","key":"10.1016\/j.jaac.2026.01.009_bib58","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1176\/ps.2010.61.12.1239","article-title":"Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics","volume":"61","author":"Lang","year":"2010","journal-title":"Psychiatr Serv"},{"issue":"7","key":"10.1016\/j.jaac.2026.01.009_bib59","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2026.01.009_bib60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/jcpp.14059","article-title":"Safer and targeted use of antipsychotics in youth: an embedded, pragmatic randomized trial","volume":"66","author":"Penfold","year":"2025","journal-title":"J Child Psychol Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2026.01.009_bib61","doi-asserted-by":"crossref","first-page":"e1577","DOI":"10.1542\/peds.2010-1361","article-title":"Treatment of maladaptive aggression in youth: CERT Guidelines II. Treatments and ongoing management","volume":"129","author":"Scotto Rosato","year":"2012","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.jaac.2026.01.009_bib62","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/pds.1559","article-title":"Somnolence effects of antipsychotic medications and the risk of unintentional injury","volume":"17","author":"Said","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.jaac.2026.01.009_bib63","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/0706743718779950","article-title":"Harms of antipsychotics in children and young adults: a systematic review update","volume":"63","author":"Pillay","year":"2018","journal-title":"Can J Psychiatry"},{"issue":"2","key":"10.1016\/j.jaac.2026.01.009_bib64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/cap.2019.0087","article-title":"Metabolic monitoring rates of youth treated with second-generation antipsychotics in usual care: results of a large US national commercial health plan","volume":"30","author":"Hayden","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856726000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856726000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:20:25Z","timestamp":1793128825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856726000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":63,"alternative-id":["S0890856726000171"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2026.01.009","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-Generation Antipsychotics and Real-World Outcomes in Youth With On- and Off-Label Indications","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92026 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}